BET protein antagonist JQ1 is synergistically lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD

Molecular Cancer Therapeutics

Volumn 13, Issue 10, 2014, Pages 2315-2327

  Fiskus, Warren ^a   Sharma, Sunil ^b   Qi, Jun ^c   Shah, Bhavin ^d   Devaraj, Santhana G T ^d   Leveque, Christopher ^d   Portier, Bryce P ^d   Iyer, Swaminathan ^d   Bradner, James E ^c   Bhalla, Kapil N ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BIM PROTEIN; BRD4 PROTEIN; CD34 ANTIGEN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; FLT3 LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PANOBINOSTAT; PONATINIB; PROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN TYROSINE KINASE INHIBITOR; QUIZARTINIB; SHORT HAIRPIN RNA; STAT5 PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BRD4 PROTEIN, HUMAN; CD135 ANTIGEN; FLT1 PROTEIN, HUMAN; FLT3 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; NUCLEAR PROTEIN; PYRIDAZINE DERIVATIVE; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE; VASCULOTROPIN RECEPTOR 1;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLAST CELL; BLAST PROGENITOR CELL; BONE MARROW PROGENITOR CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DRUG EXPOSURE; GENE SILENCING; HUMAN; HUMAN CELL; IC50; INTERNAL TANDEM DUPLICATION; LEUKEMIA CELL LINE; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; ENZYMOLOGY; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MOUSE; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; AZEPINES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, ACUTE; MICE; NUCLEAR PROTEINS; PYRIDAZINES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84925666467     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0258     Document Type: Article

References (50)

1. Verstraete K, Savvides SN. Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases. Nat Rev Cancer 2012;12:753-66
2. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010;116:5089-102.
3. Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 2000;14:1766-76
4. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012;485:260-3.
5. Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 2012;26:2176-85.
6. Smith CC, Shah NP. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. ASCO Educ Book 2013:313-8.
7. Shah NP, Talpaz M, Deininger MW, Mauro MJ, Flinn IW, Bixby D, et al. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. Br J Haematol 2013;162:548-52.
8. Taylor SJ, Dagger SA, Thien CB, Wikstrom ME, Langdon WY. Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling. Blood 2012;120:4049-57.
9. Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol 2013;31:3681-7.
10. Ostronoff F, Estey E. The role of quizartinib in the treatment of acute myeloid leukemia. Expert Opin Investig Drugs 2013;22:1659-69.
11. Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013;121:3165-71.
12. Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG, et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 2009;113:4052-62.
13. Piloto O, Wright M, Brown P, Kim KT, Levis M, Small D. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 2007;109:1643-52.
14. Weisberg E, Sattler M, Ray A, Griffin JD. Drug resistance in mutant FLT3-positive AML. Oncogene 2010;29:5120-34.
15. Sato T, Yang X, Knapper S, White P, Smith BD, Galkin S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 2011;117:3286-93.
16. Zheng R, Bailey E, Nguyen B, Yang X, Piloto O, Levis M, et al. Further activation of FLT3 mutants by FLT3 ligand. Oncogene 2011;30:4004-14.
17. Levis M. FLT3/ITD AML and the law of unintended consequences. Blood 2011;117:6987-90.
18. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Disc 2012;11:384-400.
19. Wu SY, Chiang CM. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 2007;282:13141-5.
20. Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer 2012;12:465-77.
21. Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell 2013;152:1237-51.
22. Patel MC, Debrosse M, Smith M, Dey A, Huynh W, Sarai N, et al. BRD4 coordinates recruitment of pause release factor P-TEFb and the pausing complex NELF/DSIF to regulate transcription elongation of interferon-stimulated genes. Mol Cell Biol 2013;33:2497-507.
23. Nechaev S, Adelman K. Pol II waiting in the starting gates: Regulating the transition from transcription initiation into productive elongation. Biochim Biophys Acta 2011;1809:34-45.
24. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524-8.
25. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067-73.
26. Seal J, Lamotte Y, Donche F, Bouillot A, Mirguet O, Gellibert F, et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett 2012;22:2968-72.
27. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-917.
28. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013;153:320-34.
29. Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MGM, Qi J, et al. Discovery of characterization of super enhancers-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013;24:777-790
30. Barboric M, Kohoutek J, Price JP, Blazek D, Price DH, Peterlin BM. Interplay between 7SK snRNA and oppositely charged regions in HEXIM1 direct the inhibition of P-TEFb. EMBO 2005;24:4291-303.
31. Dames SA, Schonichen A, Schulte A, Barboric M, Peterlin BM, Grzesiek S, et al. Structure of the cyclin T binding domain of Hexim1 and molecular basis for its recognition of P-TEFb. Proc Natl Acad Sci 2007;104:14312-7.
32. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011;108:16669-16674.
33. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478:529-33.
34. Fiskus W, Sharma S, Qi J, Valenta J, Schaub L, Shah B, et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myeloid leukemia (AML) cells. Mol Cancer Ther 2014;13:1142-54.
35. Dawson MA, Gudgin EJ, Horton SJ, Glotopoulos G, Meduri E, Robson S, et al. Recurrent mutations including NPM1c activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia 2014;28:311-20
36. Fiskus W, Rao R, Fernandez P, Herger B, Yang Y, Chen J, et al. Molecular and biologic characterization and drug-sensitivity of pan histone deacetylase inhibitor resistant acute myeloid leukemia cells. Blood 2008;112:2896-905.
37. Fiskus W, Verstovsek S, Manshouri T, Rao R, Balusu R, Venkannagari S, et al. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res 2011;17:7347-58
38. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009;114:2733-43.
39. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
40. Balusu R, Fiskus W, Rao R, Chong DG, Nalluri S, Mudunuru U, et al. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood 2011;118:3096-106.
41. Parmar A, Marz S, Rushton S, et al. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first generation FLT3 tyrosine kinase inhibitors. Cancer Res 2011;71:4696-706.
42. Natarajan K, Xie Y, Burcu M, Linn DE, Qiu Y, Baer MR. Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication. PloS One 2013;8:e74653.
43. Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, et al. SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia. Cancer Cell 2014;25:226-42.
44. Keegan K, Li C, Li Z, Ma J, Ragains M, Coberly S, et al. Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia. Mol Cancer Ther 2014:13:880-9.
45. Ma H, Nguyen B, Li L, Greenblatt S, Williams A, Zhao M, et al. TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo. Blood. 2014;123:1525-34.
46. Liu S, Walker SR, Nelson EA, Cerulli R, Xiang M, Toniolo PA, et al. Targeting STAT5 in hematological malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol Cancer Ther 2014;13:1194-205.
47. Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood 2013;122:3607-15.
48. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014;506:328-3
49. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011;17:1086-93.
50. Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrozek K, Becker H, et al.Astem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia 2013;27:2023-31.